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Introduction
Polycystic ovary syndrome (PCOS) is considered as one of 
the current disorders of the endocrine system in women 
of reproductive age (1-3). The epidemiological studies 
indicated that the incidence of PCOS varies in the world 
with a range of 2.2% to 26% (2,4). Such incidence is 43% 
to 46% in the United States, 37.4% in Germany, and 16% 
in Italy (5). The typical complications of PCOS include 
polycystic ovaries, elevated luteinizing hormone, hyper-
androgenism, chronic anovulation along with oligo-
amenorrhea, obesity, and infertility (6). PCOS could be 
taken into account as a metabolism-centered syndrome 
such as insulin resistance syndrome or some other risk 
factors, including cardiovascular diseases, hypertension, 
and/or dyslipidemia (7). Although the mechanism 
underlying the pathogenesis of PCOS is still elusive, this 
syndrome is concomitant with hormonal perturbation, 
such as a diminished concentration of progesterone 
and heightened levels of testosterone, estrogen and 
luteinizing hormone (8-10). In patients afflicted with both 
hyperandrogenism and PCOS, there is a strong association 
between the hyperinsulinemia and hyperandrogenism as 
the concentration of insulin shows a strong correlation 
with adrenal steroid excretion (11). On the other hand, 
in patients with PCOS, hyperinsulinemia is concurrent 
with heightened levels of low-density lipoprotein (LDL), 
very low-density lipoprotein (VLDL), triglyceride, 
total cholesterol (12) and reduced level of high-density 
lipoproteins (HDL) (13). Additionally, besides insulin 
resistance, the metabolism of lipid in females suffered 
from PCOS may be altered by ovarian- or adrenal- 
excretion of sex steroid hormones. Effects of sex steroids 
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Introduction 
Throughout the history of the world, the ones who had 
confronted the bitterest face of poverty and war had al-
ways been the women. As known poverty and war affects 
human health either directly or indirectly, the effects of 
this condition on health and status of women in the so-
ciety should not be ignored. This study intends to cast 
light on the effects of war and poverty on the reproductive 
health of women. For this purpose, the face of war affect-
ing the women, the problem of immigration, inequalities 
in distribution of income based on gender and the effects 
of all these on the reproductive health of women will be 
addressed.
War and Women’s Health
Famine, synonymous with war and poverty, is clearer for 
women; war means eep disadvantages such as full de-
stru tion, loss of future and uncertainty for women. Wars 
are conflicts that destroy families, societies and cultures 
that negatively affect the health of community and cause 
violation of human rights. According to the data of World 
Health Organization (WHO) and World Bank, in 2002 
wars had been among the first ten reasons which killed 
the most and caused disabilities. Civil losses are at the rate 
of 90% within all losses (1).
Wa  has many negative effects on human health. One f 
these is its effect of shortening the average human life. 
According to the data of WHO, the average human life is 
68.1 years for males and 72.7 years for females. It is being 
thought that severe military conflicts in Africa shorten 
the expected lifetime for more than 2 years. In general, 
WHO had calculated that 269 thousand people had died 
in 1999 due to the effect of wars and that loss of 8.44 mil-
lion healthy years of life had occurred (2,3).
Wars negatively affect the provision of health services. 
Health institutions such as hospitals, laboratories and 
health centers are direct targets of war. Moreover, the wars 
cause the migration of qualified health employees, and 
thus the health services hitches. Assessments made indi-
cate that the effect of destruction in the infrastructure of 
health continues for 5-10 years even after the finalization 
of conflicts (3). Due to resource requirements in the re-
structuring investments after war, the share allocated to 
health has decreased (1).
Mortalities nd Morbidities
The ones w o are most aff cted from wars are women and 
children. While deaths depending on direct violence af-
fect the male population, the indirect deaths kill children, 
women and elders more. In Iraq between 1990-1994, in-
fant deaths had shown this reality in its more bare form 
with an increase of 600% (4). The war taking five years 
increases the child deaths under age of 5 by 13%. Also 47% 
of all the refugees in t e world and 50% of asylu  seekers 
and displaced peopl  ar  women and girl  and 44% ref-
ugees and asylum seekers are childre  under the age of 
18 (5).
As the result of wars and armed conflicts, women are 
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on lipid metabolism are complicated by the activities of 
both estrogens and androgens which are involved in this 
scenario (14, 15). In addition to metabolic alteration, PCOS 
is attributed to the alterations occurred in the secretion of 
reproductive hormones, including the increased ratio of 
the luteinizing hormone (LH) to the follicle-stimulating 
hormone (FSH) (i.e. LH/FSH) and circulating androgens 
contributing to the typical symptoms of PCOS, such as 
hirsutism, acne, as well as acanthosis nigricans (16).
Herbal medicines have long been used for the 
treatment of female reproductive disorders as they 
contain pharmacologically active components showing 
promising effects in patients with (17) PCOS, diabetes, 
and cardiovascular diseases (18,19). Galega ofﬁcinalis 
is a natural plant belonging to the Middle East (20) and 
southeastern part of Europe (21). In the Medieval period, 
it was used as a therapy for diabetes (20, 22). One of the 
main components of G. officinalis is alkaloid galegine 
possessing hypoglycemic properties in animal models 
(23). Furthermore, it was shown that G. officinalis has a 
remarkable effect on body weight loss and insulin (24). 
Therefore, for the treatment of diabetes, the use of this 
herb can open a new avenue by increasing the sensitivity 
of tissues to insulin and reducing the tissue damage (19).
However, since PCOS results in damage to organs 
and tissues of the human body, such as the ovaries, the 
kernel goal of the study was to examine the effects of G. 
officinalis extract on the damage of ovarian tissue as well 
as biochemical factors altered as a result of PCOS.
Materials and Methods
In the present study, 32 adult female Wistar rats (weighing 
200-250 g) were used. All rats were procured from Razi 
Institute, Mashhad, Iran. They were carefully kept in the 
animal house under standard conditions (temperature 
22°C and 12 h/12 h light/dark cycle) and had free access 
to food and water. 
Experimental Groups and Study Design
Rats were randomly divided into 4 groups (n=8/group), as 
one control group and three experimental groups.
1: Healthy or control group (control).
2: PCOS control group (PCO), in which PCOS was 
induced by an intramuscular injection (IM) of 16 mg/kg 
estradiol valerate (Sigma, Germany) (a single dose) which 
was dissolved in 0.2 ml of sesame oil (25).
3: PCOS group (PG200) was treated with the 
hydroalcoholic extract of G. officinalis (200 mg/kg/orally/
daily) for 2 weeks.
4: PCOS group (PG400) was treated with the 
hydroalcoholic extract of G. officinalis (400 mg/kg/orally/
daily) for 2 weeks.
The vaginal smear was examined daily and estrus cycle 
was confirmed in all rats. After the treatment period, all 
rats were anesthetized with ketamine/xylazine (5/1 mg/
kg) (19,26), then the blood samples were taken from 
the hearts of all rats and the serum was separated by 
centrifugation at 3500 g. The obtained sera were kept at 
-70°C until the further analysis
Preparation of Hydroalcoholic Extract of Galega officinalis
To prepare the extract of G. officinalis, half a kilogram of 
this plant was purchased from Dineh Company (Iran). 
For extraction, the plant was firstly dissolved in 2 liters 
of alcohol 50% and distilled water and then was kept 
for 48 hours at room temperature on a shaker (Thermo 
Fisher). Then, the solution was filtered and centrifuged 
for 5 minutes at 3000 rpm. At the end of this process, the 
resulting solution was poured into an open-top container 
and the solvent was evaporated. Finally, to achieve an 
appropriate concentration, the extract was dissolved in 
normal saline.
Measurement of Serum Glucose Level
At the commencement of this study, in samples which 
were obtained from the tip of the vein of rats’ tail, the 
level of fasting blood sugar (FBS) was measured using 
a portable glucometer. Accordingly, at the end of the 
experiment period, the serum glucose level was analyzed 
using a commercial kit (Pars Azmun, Iran). The value was 
expressed as mg/dL.
Measurement of Serum Insulin Level
The measurement of serum insulin concentration was 
carried out by ELISA (enzyme-linked immunosorbent 
assay) using a commercial kit specified for rats (Mercodia, 
Sweden). Serum insulin levels were expressed as mIU/mL.
Measurement of the Serum Levels of Testosterone, 
Estrogen, FSH, LH, and Aromatase
Serum hormone levels were quantified using ELISA kits 
for testosterone and estrogen (Demeditec, Germany). 
The absorbance was recorded at 405 nm for analyzing 
testosterone and estrogen. Correspondingly, the serum 
levels of aromatase, FSH, as well as LH were also 
determined using an ELISA kit (Cusabio, China).
Histological Study
The histological examinations were carried out based on 
previous experimental studies. The ovarian samples were 
immersed in the formalin 10% solution for 72 hours. After 
fixation, they were dehydrated and embedded in paraffin. 
Then they were cut into 5 microns thick sections to make 
tissue samples. They were deparaffinized, stained with 
hematoxylin-eosin (H&E), then, evaluated the sections of 
each ovarian tissue (n = 7) from the cortex of ovary to the 
medulla in a spiral and clockwise direction. In each of the 
ovarian slide, the number of primary Follicles, pre-antral, 
antral, cystic follicles and yellow body were enumerated. 
All sections were assessed by an optical microscope 
(NIKON) at a magnification of ×100 (27-29).
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Statistical Analysis
The statistical analysis of the present study was carried out 
using SPSS software 19.0. All data were presented as mean 
± standard error of mean (SEM) and were compared using 
one-way ANOVA and Tukey post hoc test. P < 0.05 was 
considered statistically significant.
Results
Serum Level of FBS
In PCOS group, the serum level of FBS was significantly 
higher compared to control group (P < 0.05) (Figure 1). In 
treated groups received 200 and 400 mg/kg of G. officinalis 
extract, the serum level of glucose was significantly lower 
in comparison to the group affected by PCOS (P < 0.05).
Serum Level of Insulin 
In PCOS group, the serum level of insulin was statistically 
increased in comparison to control group (P < 0.05) 
(Figure 2). However, it was significantly decreased in 
treated groups, PG 200 and PG 400, in comparison to the 
group affected by PCOS (P < 0.05).
The Serum Levels of Testosterone, Estrogen, LH, FSH and 
Aromatase
The serum levels of testosterone, estrogen, FSH, and LH 
were shown in Table 1. According to Table 1, the serum 
testosterone level was significantly higher in PCOS group 
compared to control group (P < 0.05). Moreover, in both 
treated groups (PG200 and PG400) the serum levels of 
testosterone were significantly reduced in comparison to 
PCOS group (P < 0.05). Moreover, there was a significant 
difference in levels of serum estrogen between PCOS 
and control groups (P < 0.05). Serum estrogen level was 
increased in treated groups when compared to PCOS 
group (P < 0.05). In PCOS group, there was a significant 
increase in serum levels of LH and FSH compared to 
control group (P < 0.05). Conversely, in both treated 
groups, the serum levels of gonadotropin hormones (LH 
and FSH) were significantly decreased in comparison 
with PCOS group (P < 0.05). Likewise, in PCOS group, 
the serum level of aromatase was significantly decreased 
compared to control group (P < 0.05) (Figure 3). In both 
groups treated with G. officinalis, the serum aromatase 
level was significantly increased compared to PCOS group 
(P < 0.05).
The Number of Follicles
The number of pre-antral follicles, antral follicles, cystic 
follicles and yellow bodies is presented in Table 2 and 
Figure 4 shows the light microscope micrograph of 
ovaries. However, the number of primary follicles was 
significantly declined in PCOS group in comparison to 
control group (P < 0.05). Moreover, a significant difference 
was observed between PCOS group and two treated groups 
(P < 0.05). In PCOS group, the number of pre-antral 
follicles was significantly declined compared to control 
group (P < 0.05), while the number of pre-antral follicles 
was significantly higher in both treated groups compared 
to PCOS group (P < 0.05). On the other hand, in PCOS 
group, enumerating the antral follicles showed a significant 
decrease in comparison to control group (P < 0.05). 
Furthermore, in both treated groups in comparison to 
PCOS group, the number of antral follicles significantly 
increased (P < 0.05). On the other hand, in PCOS group, 
the number of cystic follicles significantly increased when 
compared to control group (P < 0.05). Treatment with G. 
officinalis extract significantly decreased the number of 
cystic follicles in comparison to rats with PCOS received 
no therapy (P < 0.05). In addition, evaluating the number 
of yellow bodies showed a significant decrease in PCOS 
group compared to control group (P < 0.05). Additionally, 
Figure 1. The Serum Level of Glucose in the Experimental and Control 
Groups.
Control: healthy control group; PCOS: PCOS group that received normal 
saline by oral gavage; PG200: PCOS group treated with hydroalcoholic 
extract (200 mg/kg) of Galega officinalis; PG400: PCOS group treated 
with hydroalcoholic extract (400 mg/kg) of Galega officinalis. All data are 
displayed as mean ± SE. The asterisk + shows significant difference with 
control group and the symbol of * means the significant difference with 
PCOS group (P<0.05).
Figure 2. The Serum level of Insulin in the Experimental and Control 
Groups.
Control: healthy control group; PCOS: PCOS group that received normal 
saline by oral gavage; PG200: PCOS group treated with hydroalcoholic 
extract (200 mg/kg) of Galega officinalis; PG400: PCOS group treated 
with hydroalcoholic extract (400 mg/kg) of Galega Officinalis. All data are 
displayed as mean ± SE. The asterisk + shows significant difference with 
control group and the symbol of * means the significant difference with 
PCOS group (P < 0.05).
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in both treated groups, PG 200 and PG 400, a significant 
increase in the number of yellow bodies was observed in 
comparison to the group affected by PCOS (P < 0.05).
Discussion
Our results showed that G. officinalis had the beneficial 
effects on the levels of FBS. Similar results were found 
in a study showed that the decrease in FBS is associated 
with galegine, a guanidine compound exists in the plant 
(24). Moreover, Shen et al indicated that G. officinalis has 
a similar effect to that of metformin because of possessing 
Bygvandyn composition. Therefore, it would be plausible 
Table 1. The Serum Levels of Testosterone, Estrogen, LH, FSH in All of the Studied Groups
Groups LH (ng/mL) FSH (ng/mL) Testosterone (ng/mL) Estrogen (pg/mL)
Control 1.99±0.081 2.22 ±0.03 0.552 ± 0.14 52.0 ± 2.55
PCOS 3.26 ± 0.177* 5.32±0.50* 3.25 ± 0.17* 30.25±1.89*
PG200 2.25 ± 0.235+ 3.25 ± 0.31+ 0.852 ± 0.035+ 38.50 ± 2.08+
PG400 2.05 ± 1.70+ 2.98 ± 0.19+ 0.670 ± 0.023+ 44.42 ± 2.57+
Control: healthy control group; PCOS: PCOS group that received normal saline by oral gavage; PG200: PCOS group treated with hydroalcoholic extract 
(200 mg/kg) of Galega officinalis, PG400: PCOS group treated with hydroalcoholic extract (400 mg/kg) of G. officinalis. All data are displayed as Mean 
± SE. 
The asterisk * shows significant difference with control group and the symbol of + means the significant difference with PCOS group (P<0.05).
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Figure 3. The Serum Activity of Aromatase in the Experimental and Control 
Groups.
Control: healthy control group; PCOS: PCOS group that received normal 
saline by oral gavage; PG200: PCOS group treated with hydroalcoholic 
extract (200 mg/kg) of Galega officinalis; PG400: PCOS group treated with 
hydroalcoholic extract (400 mg/kg) of G. officinalis. All data are displayed 
as mean ± SE. The asterisk + shows significant difference with control 
group and the symbol of * means the significant difference with PCOS 
group (P < 0.05).
Table 2. The Number of Primary, Per-antral, Antral, Cystic Follicles and Yellow Body in Different Groups
Groups Primary Follicles Pre-antral Follicles Antral Follicles Cystic Follicles Yellow Body
Control 19.4 ± 1.14 30 ± 1.58 17.6 ± 1.14 0 9.2±0.83
PCOS 7.6 ± 1.14* 7.4 ± 1.14* 3.8 ± 0.83* 6.6 ± 0.54* 1.6±0.89*
PG200 13.4 ± 1.14+ 19 ± 1.58+ 10.4 ± 1.58+ 2.4 ± 0.54+ 4.8± 0.83+
PG400 16.8 ± 0.83+ 23 ± 1.14+ 13.6 ± 1.14+ 1.2 ± 0.83+ 6.4± 0.54+
Control: healthy control group; PCOS: PCOS group that received normal saline by oral gavage; PG200: PCOS group treated with hydroalcoholic extract (200 mg/
kg) of Galega officinalis; PG400: PCOS group treated with hydroalcoholic extract (400 mg/kg) of G. officinalis. All data are displayed as mean ± SE. The asterisk * 
shows significant difference with control group and the symbol of + means the significant difference with PCOS group (P < 0.05).
that G. officinalis could be applied for decreasing the blood 
sugar (30). Uchiyama et al observed that antioxidants may 
preclude or postpone the cellular malfunction in diabetes 
through the protection against toxic levels of glucose (31).
Insulin resistance followed by compensatory 
hyperinsulinemia is considered as the most prominent 
features among complications resulted from PCOS (32). 
Insulin resistance has been reported in 25 to 60% of women 
afflicted with PCOS (33). It has also been described that 
G. officinalis is able to decrease hyperinsulinemia (24). 
Moreover, the serum level of insulin was decreased in the 
groups treated with G. officinalis compared with PCOS 
group. Such decrease may stem from the existence of 
complexes such as resin, glycoside, saponins, and steroids. 
Therefore, antioxidant existing in those compounds 
can protect the beta cells of the pancreas from damage 
caused by oxidative stress (19). Some flavonoids can 
modify the insulin-secreting capacity and modulate beta 
cell apoptosis. It should be noted that the decrease in 
antioxidant capacity has been shown to have a correlation 
with insulin resistance (34). 
A number of studies have illustrated that patients with 
PCOS have higher levels of LH, FSH, and testosterone, 
while the level of estrogen is lower in patients affected by 
PCOS (35). It has been indicated that the serum activity of 
aromatase is declined in PCOS patients (35).
The present study showed that PCOS caused a significant 
increase in the levels of testosterone, LH, as well as FSH, 
while the levels of aromatase and estrogen significantly 
decreased compared to control group. Treatment with G. 
officinalis extract is capable of increasing the serum levels 
of aromatase and estrogen and decreasing the levels of 
LH, FSH, and testosterone. Genazzani et al showed that in 
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patients suffered from PCOS, treatment with metformin 
can reduce the serum levels of estradiol, LH, as well as 
insulin (36). On one hand, the reduction in the serum 
activity of aromatase in PCOS group may be correlated 
with the decline in serum estrogen level. Christine et al 
reported that the serum level of estrogen is decreased in 
PCOS, while the serum levels of LH, FSH, and testosterone 
are increased in the patients with PCOS (37). Reducing 
the hyperinsulinemia, whether it is caused by weight loss 
or the administration of metformin/troglitazone, results 
in a reduction of plasma levels of LH. However, some 
studies showed that a decrease in plasma levels of LH 
in response to the reduction of insulin may be similar 
to a phenomenon in which reduced plasma androgen is 
caused by a reduction in ovarian androgen secretion by 
insulin (38).
Cytochrome P450c-17α is amongst the enzymes whose 
activity is increased in some disorders such as PCOS. 
Furthermore, cytochrome P450c-17α is the main enzyme 
in the synthesis of androgens, which is directly incited by 
insulin in patients who suffer from PCOS. Yet, metformin 
can lead to decrease in the plasma levels of androgens, LH, 
and IGF-I by reducing the level of insulin, which, in turn, 
resulted in the reduction of action of this enzyme (39). 
Insulin is able to prevent the secretion of sex hormone-
binding globulin (SHBG) by acting on the liver, hence, 
the circulating androgens would be increased (40). The 
incidence of involuntary ovulation can be increased 
in women with PCOS who take metformin since it can 
diminish the levels of insulin (41). Mu et al showed that 
Figure 4. The Histological Findings in Ovaries of the Experimental and the 
Control Groups.
A: healthy control group; B: PCOS group that received normal saline by 
oral gavage; C: PG200: PCOS group treated with hydroalcoholic extract 
(200 mg/kg) of Galega officinalis; D: PG400: PCOS group treated with 
hydroalcoholic extract (400 mg/kg) of G. officinalis. Scale bar = 100 
micrometers (x100)
the decline in the plasma concentration of estrogens by 
troglitazone in PCOS may be as a result of the reduced 
aromatization which in turn leads to the reduction of 
circulating insulin level (42). Additionally, Maraca et 
al reported that in women with PCOS, treatment with 
metformin could decrease the aromatase activity in 
response to FSH (41).
In the present study, in PCOS group, there was a 
significant decrease in the number of follicles, while the 
number of cystic follicles was significantly increased. These 
phenomena might originate from hyperandrogenism that 
leads to the generation of cystic follicles and reduction 
of the number of normal follicles (39). Manneras et al 
reported that PCOS increased the number of atretic 
antral follicles and decreased the number of healthy antral 
follicles (43). Moreover, Badawy et al reported that PCOS 
caused a reduction in the number of healthy follicles in 
rats with PCOS (44). The results showed that treatment 
with G. officinalis could increase the number of follicles 
and reduce the number of cystic follicles compared to 
PCOS group. It can stem from the effects of G. officinalis 
on serum insulin level and insulin resistance, which 
are possibly pertained to the presence of Bygvanydyn, 
flavonoid, saponins in G. officinalis. It has been indicated 
that these compounds can decrease the insulin resistance 
and prevent the hyperandrogenism (24,30). However, the 
effects of G. officinalis on preventing the generation of 
cystic follicles in the groups treated with PG 200 and PG 
400 may be due to anti-hyperandrogenic properties of this 
herb.
In conclusion, our result showed that G. officinalis extract 
has a striking effect on the level of steroid hormones, the 
serum aromatase activity, and the serum glucose level in 
rats. Moreover, the hydroalcoholic extract of G. officinalis 
could decrease the number of cystic follicles and increase 
the number of normal follicles. The beneficial effects of G. 
officinalis may be due to the presence of antioxidant and 
insulin-like agents such as Bygvanydyn, resin, glycoside, 
and saponins.
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